Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00928512 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 237
- Enrollment target
NCT00928512 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 237 participants.
The verdict
NCT00928512, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 237 participants
- Enrollment target
Study Summary
This study will assess at Week 16 the efficacy and safety of AIN457 at different doses in patients with active RA despite stable MTX therapy. Treatment will continue up to Week 48 with a safety follow-up at Week 60 to assess the long term efficacy and safety of AIN457 treatment in combination with MTX in RA.
Interventions
- DRUG Placebo
- DRUG Secukinmab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2009-07 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00928512
The ClinicalTrials.gov registry entry for NCT00928512 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 237 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00928512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00928512 about?
NCT00928512 is a clinical study titled "Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)". This study will assess at Week 16 the efficacy and safety of AIN457 at different doses in patients with active RA despite stable MTX therapy. Treatment will continue up to Week 48 with a safety follow-up at Week 60 to assess the long term efficacy and safety of AIN457 treatment in combination with M...
What is the current status of trial NCT00928512?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 237 participants. The study started on 2009-07. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00928512?
The interventions under investigation include: Placebo (DRUG), Secukinmab (DRUG).
Who is sponsoring clinical trial NCT00928512?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.